JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Prognostic and Predictive Biomarkers of Oligometastatic NSCLC: New Insights and Clinical Applications

  • 0Department of Pulmonary Diseases, GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, The Netherlands.
Jto Clinical and Research Reports +

|

December 30, 2024

|

December 30, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Identifying reliable biomarkers for oligometastatic non-small cell lung cancer (NSCLC) is crucial for effective treatment selection. Current predictive and prognostic biomarkers show promise but require further validation in clinical trials.

Area Of Science

  • Oncology
  • Biomarker Research
  • Translational Medicine

Background

  • Oligometastatic non-small cell lung cancer (NSCLC) presents a unique clinical challenge.
  • The identification of reliable predictive and prognostic biomarkers is essential for guiding treatment decisions in this patient population.

Purpose Of The Study

  • To review current data on biomarkers for oligometastatic NSCLC.
  • To assess the potential extrapolation of biomarkers from other NSCLC stages to the oligometastatic setting.
  • To highlight the need for validated biomarkers to optimize patient selection for locoregional therapies.

Main Methods

  • Literature review of existing data on predictive and prognostic biomarkers in NSCLC.
  • Exploration of biological attributes from tumor tissue, circulating cells, tumor microenvironment, and imaging findings.
  • Analysis of challenges including lack of clear OMD definition and heterogeneous study populations.

Main Results

  • Multiple promising biomarkers (tissue-based, circulating, imaging) are under investigation for oligometastatic NSCLC.
  • Current biomarkers are in early development stages, lacking prospective validation.
  • Heterogeneity in OMD definitions and patient populations complicates biomarker assessment.

Conclusions

  • Validated biomarkers are critically needed to define true oligometastatic disease (OMD) and predict treatment outcomes.
  • Liquid biopsies and imaging-based biomarkers are promising for future evaluation due to ease of access and potential for longitudinal monitoring.
  • Prospective, large-scale, homogeneous studies are required to confirm the prognostic and predictive value of identified biomarkers.

Keywords: